These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1627440)

  • 21. Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease.
    Chiaravalloti A; Stefani A; Fiorentini A; Lacanfora A; Stanzione P; Schillaci O
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2137-43. PubMed ID: 25007849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography imaging of transplant function.
    Brooks DJ
    NeuroRx; 2004 Oct; 1(4):482-91. PubMed ID: 15717049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroimaging in Parkinson's disease.
    Brooks DJ
    NeuroRx; 2004 Apr; 1(2):243-54. PubMed ID: 15717025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.
    Kornhuber J; Brücke T; Angelberger P; Asenbaum S; Podreka I
    J Neural Transm Gen Sect; 1995; 101(1-3):95-103. PubMed ID: 8695060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
    Poewe W
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
    Thobois S; Vingerhoets F; Fraix V; Xie-Brustolin J; Mollion H; Costes N; Mertens P; Benabid AL; Pollak P; Broussolle E
    Arch Neurol; 2004 Nov; 61(11):1705-9. PubMed ID: 15534182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo and in vitro studies of the dopaminergic system in movement disorders.
    Playford ED; Brooks DJ
    Cerebrovasc Brain Metab Rev; 1992; 4(2):144-71. PubMed ID: 1627440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applications of clinical dopamine imaging.
    Lindsey KP; Gatley SJ
    Neuroimaging Clin N Am; 2006 Nov; 16(4):553-73, vii-viii. PubMed ID: 17148019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1996; 69():497-501. PubMed ID: 8615171
    [No Abstract]   [Full Text] [Related]  

  • 30. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F; Ricci A; Tayebati SK; Zaccheo D
    Ital J Anat Embryol; 2002; 107(3):145-67. PubMed ID: 12437142
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.